Acelyrin

Acelyrin (NASDAQ:SLRN) shares rose as the company announced an investor meeting to present updated Phase 2 trial data for lonigutamab, targeting thyroid eye disease (TED).

ACELYRIN, INC. announces a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), discuss unmet needs in TED, and reveal the Phase 3 LONGITUDE program design. The event will feature company executives and external clinicians, including Drs. Andrea Kossler and Prem Subramanian.

ACELYRIN, INC. announces a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), featuring clinician insights and the Phase 3 LONGITUDE program design. The event includes a Q&A session, with a webcast available post-event.

ACELYRIN, INC. announces a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), discuss unmet needs, and reveal the Phase 3 LONGITUDE program design. The event includes a Q&A session and will be archived on the company's website.

ACELYRIN, INC. announces a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), highlighting its efficacy and safety. The event will also discuss the Phase 3 LONGITUDE program and feature expert insights from Drs. Andrea Kossler and Prem Subramanian.

ACELYRIN, INC. announces a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), discuss unmet needs, and reveal the Phase 3 LONGITUDE program design. The event includes presentations by company executives and external clinicians, with a Q&A session and webcast recording available post-event.

ACELYRIN, INC. will host a virtual investor event on January 6, 2025, to share updated Phase 2 data and Phase 3 program design for subcutaneous lonigutamab, targeting Thyroid Eye Disease (TED). The event includes presentations from ACELYRIN executives and external clinicians, focusing on lonigutamab's efficacy, safety, and the LONGITUDE program design.

ACELYRIN, INC. announced a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), showcasing its efficacy and safety. The event will also discuss the Phase 3 LONGITUDE program and feature insights from external clinicians. Lonigutamab, a subcutaneous monoclonal antibody, targets IGF-1R, offering potential for improved treatment in TED.

ACELYRIN, INC. announced a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), discuss unmet needs, and reveal the Phase 3 LONGITUDE program design. The event will include ACELYRIN executives and external clinicians, with a Q&A session and webcast available post-event.

ACELYRIN, Inc. shares rose after announcing Phase 2 data for Subcutaneous Lonigutamab, indicating potential best-in-class efficacy and safety in Thyroid Eye Disease. The data and Phase 3 program design will be revealed at a virtual event. Shares are up 14.6% to $3.78.